{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T20:37:27Z","timestamp":1774384647675,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13555-026-01670-9","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:25:56Z","timestamp":1770708356000},"page":"1599-1616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Satisfaction Using Guselkumab Self-administered Using the One-Press Device for Treatment of Moderate-to-Severe Psoriasis: Results from a National, Prospective, Real-World Study in Portugal (CERES Study)"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"first","affiliation":[]},{"given":"Jo\u00e3o Teles","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Antunes","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Mendes-Bastos","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Brasileiro","sequence":"additional","affiliation":[]},{"given":"V\u00edtor","family":"Neto","sequence":"additional","affiliation":[]},{"given":"Martinha","family":"Henrique","sequence":"additional","affiliation":[]},{"given":"Rita","family":"Pimenta","sequence":"additional","affiliation":[]},{"given":"Sofia","family":"Magina","sequence":"additional","affiliation":[]},{"given":"Diana","family":"Louren\u00e7o","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Mota","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"issue":"2","key":"1670_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377\u201385.","journal-title":"J Invest Dermatol"},{"key":"1670_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20061475.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1670_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.20344\/amp.19048","volume":"36","author":"T Torres","year":"2023","unstructured":"Torres T, Filipe P, Menezes Brand\u00e3o F, Figueiredo A, Pinto Soares A, Sousa Basto A, et\u00a0al. Epidemiology of psoriasis in Portugal: a population-based study. Acta Med Port. 2023;36(9):541\u20139.","journal-title":"Acta Med Port"},{"issue":"8 Suppl","key":"1670_CR4","first-page":"s216","volume":"22","author":"A Menter","year":"2016","unstructured":"Menter A. Psoriasis and psoriatic arthritis overview. Am J Manag Care. 2016;22(8 Suppl):s216\u201324.","journal-title":"Am J Manag Care"},{"key":"1670_CR5","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","volume":"2","author":"JE Greb","year":"2016","unstructured":"Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, et\u00a0al. Psoriasis. Nat Rev Dis Prim. 2016;2:16082.","journal-title":"Nat Rev Dis Prim"},{"issue":"19","key":"1670_CR6","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"Suppl 2","key":"1670_CR7","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","volume":"64 Suppl 2","author":"RG Langley","year":"2005","unstructured":"Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):ii18-23 (discussion ii4-5).","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1670_CR8","first-page":"278","volume":"63","author":"WB Kim","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278\u201385.","journal-title":"Can Fam Physician"},{"issue":"10","key":"1670_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40261-017-0550-z","volume":"37","author":"Z Chen","year":"2017","unstructured":"Chen Z, Gong Y, Shi Y. Novel biologic agents targeting interleukin-23 and interleukin-17 for moderate-to-severe psoriasis. Clin Drug Investig. 2017;37(10):891\u20139.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1670_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13555-018-0230-9","volume":"8","author":"JM Carrascosa","year":"2018","unstructured":"Carrascosa JM, Jacobs I, Petersel D, Strohal R. Biosimilar drugs for psoriasis: principles, present, and near future. Dermatol Ther. 2018;8(2):173\u201394.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1670_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/09546634.2019.1587145","volume":"31","author":"LK Ferris","year":"2020","unstructured":"Ferris LK, Ott E, Jiang J, Hong HC, Li S, Han C, et\u00a0al. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. J Dermatol Treat. 2020;31(2):152\u20139.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"1670_CR12","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/jdv.12751","volume":"29","author":"C Paul","year":"2015","unstructured":"Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et\u00a0al. Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082\u201390.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1670_CR13","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212594","volume":"8","author":"M Nogueira","year":"2019","unstructured":"Nogueira M, Torres T. Guselkumab for the treatment of psoriasis\u2014Evidence to date. Drugs Context. 2019;8:212594.","journal-title":"Drugs Context"},{"issue":"4","key":"1670_CR14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaad.2019.11.040","volume":"82","author":"K Reich","year":"2020","unstructured":"Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, et\u00a0al. Maintenance of clinical response and consistent safety profile with up to 3\u00a0years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936\u201345.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1670_CR15","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/bjd.13691","volume":"172","author":"H Kitchen","year":"2015","unstructured":"Kitchen H, Cordingley L, Young H, Griffiths CE, Bundy C. Patient-reported outcome measures in psoriasis: the good, the bad and the missing! Br J Dermatol. 2015;172(5):1210\u201321.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1670_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00403-018-1808-x","volume":"310","author":"AG Florek","year":"2018","unstructured":"Florek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res. 2018;310(4):271\u2013319.","journal-title":"Arch Dermatol Res"},{"issue":"9","key":"1670_CR17","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/jdv.14937","volume":"32","author":"CEM Griffiths","year":"2018","unstructured":"Griffiths CEM, Augustin M, Naldi L, Romiti R, Guevara-Sangines E, Howe T, et\u00a0al. Patient-dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey. J Eur Acad Dermatol Venereol. 2018;32(9):1523\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1670_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072170","author":"M Galluzzo","year":"2020","unstructured":"Galluzzo M, Tofani L, Lombardo P, Petruzzellis A, Silvaggio D, Egan CG, et\u00a0al. Use of Guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9072170.","journal-title":"J Clin Med"},{"issue":"8","key":"1670_CR19","doi-asserted-by":"publisher","first-page":"632","DOI":"10.36849\/JDD.7486","volume":"23","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Cortese A, Toso F, Vignoli CA, Fiorillo G, et\u00a0al. Real-life effectiveness and safety of guselkumab in moderate-to-severe plaque psoriasis: a 104-week retrospective single-center study. J Drugs Dermatol. 2024;23(8):632\u20139.","journal-title":"J Drugs Dermatol"},{"key":"1670_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092552","author":"M Megna","year":"2024","unstructured":"Megna M, Balato A, Caccavale S, Cacciapuoti S, Calabrese G, Di Brizzi EV, et\u00a0al. Real-life effectiveness and safety of Guselkumab in patients with psoriasis who have an inadequate response to Ustekinumab: a 3-year multicenter study. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13092552.","journal-title":"J Clin Med"},{"key":"1670_CR21","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/ced\/llaf172","volume":"50","author":"E Mortato","year":"2025","unstructured":"Mortato E, Talamonti M, Marcelli L, Megna M, Raimondo A, Caldarola G, et\u00a0al. A long-term real-life safety study of guselkumab in psoriasis patients with infectious comorbidities, malignancies or heart disease: the EARLY Study. Clin Exp Dermatol. 2025;50:1786\u201394.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1670_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s13555-022-00879-8","volume":"13","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, et\u00a0al. Real-world effectiveness of 9-12\u00a0months of guselkumab therapy among patients with moderate-to-severe plaque psoriasis in the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2023;13(2):629\u201340.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7624","key":"1670_CR23","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et\u00a0al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806\u20138.","journal-title":"BMJ"},{"issue":"3","key":"1670_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.farma.2024.07.002","volume":"49","author":"J Borr\u00e1s-Blasco","year":"2025","unstructured":"Borr\u00e1s-Blasco J, Garc\u00eda RA, Cornejo-Uixeda S, Matellanes-Palacios M, Caster\u00e1-Melchor E. Patient preference after switching guselkumab from prefilled syringe to an autoinjection pen in psoriasis and psoriatic arthritis patients. Farm Hosp (Madrid). 2025;49(3):160\u20133.","journal-title":"Farm Hosp (Madrid)"},{"issue":"10","key":"1670_CR25","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.clinthera.2006.10.006","volume":"28","author":"A Kivitz","year":"2006","unstructured":"Kivitz A, Cohen S, Dowd JE, Edwards W, Thakker S, Wellborne FR, et\u00a0al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006;28(10):1619\u201329.","journal-title":"Clin Ther"},{"issue":"1","key":"1670_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.15750","volume":"178","author":"RG Langley","year":"2018","unstructured":"Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, et\u00a0al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III navigate trial. Br J Dermatol. 2018;178(1):114\u201323.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1670_CR27","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1007\/s13555-023-01028-5","volume":"13","author":"RR McLean","year":"2023","unstructured":"McLean RR, Sima AP, Beaty S, Jones EA, Eckmann T, Low R, et\u00a0al. Durability of near-complete skin clearance in patients with psoriasis using systemic biologic therapies: real-world evidence from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2023;13(11):2753\u201368.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1670_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23116130","author":"VS Krishnan","year":"2022","unstructured":"Krishnan VS, K\u00f5ks S. Transcriptional basis of psoriasis from large scale gene expression studies: the importance of moving towards a precision medicine approach. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23116130.","journal-title":"Int J Mol Sci"},{"key":"1670_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216344","author":"VM Stacey","year":"2023","unstructured":"Stacey VM, K\u00f5ks S. Genome-wide differential transcription of long noncoding RNAs in psoriatic skin. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms242216344.","journal-title":"Int J Mol Sci"},{"issue":"10201","key":"1670_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, et\u00a0al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831\u20139.","journal-title":"Lancet"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01670-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01670-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:06:09Z","timestamp":1774371969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01670-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1670"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01670-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following conflicts of interest: Tiago Torres: AbbVie, Almirall, Amgen, Apogee Therapeutics, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers-Squibb, Celgene, Eli-Lilly, Fresenius-Kabi, Johnson & Johnson, LEO Pharma, MSD, Mylan, Novartis, Pfizer, Samsung Bioepis, Sanofi- Genzyme, Sandoz, STADA, UCB, Viatris. Conflict of Interest\u2019 section: Tiago Torres is an Editorial Board member of Dermatology and Therapy. Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Jo\u00e3o Teles Sousa: AbbVie, Eli-Lilly, Johnson & Johnson, LEO Pharma. Joana Antunes: AbbVie, Almirall, Amgen, Boehringer Ingelheim, Johnson & Johnson, LEO Pharma, Lilly, Moonlake Immunotherapeutics, Novartis and Sanofi. Pedro Mendes-Bastos: AbbVie, Almirall, Alumis, Amgen, Apogee,, Biogen, Cantabria Labs, CS Labs, Eli-Lilly, Evelo Biosciences, GlaxoSmithKline, Johnson & Johnson, LEO Pharma, L\u2019Or\u00e9al,Novartis, Organon, Pfizer, Pierre Fabre, Regeneron, Sanofi, Sanofi-Regeneron, Takeda, Teva and Viatris. Ana Brasileiro: AbbVie, Almirall, Biogen, Eli-Lilly, Johnson & Johnson, LEO Pharma, Novartis, and Sanofi. Vitor Neto: AbbVie, Johnson & Johnson. Martinha Henrique: AbbVie, Almirall, Johnson & Johnson, Novartis, LEO Pharma, Eli-Lilly, and Sanofi. Rita Pimenta: AbbVie, Almirall, Johnson & Johnson, LEO Pharma, Novartis. Sofia Magina: Abbvie, Almirall, Amgen, Eli-Lilly, Johnson & Johnson, Leo-Pharma, MSD, Novartis, Pfizer, Sanofi. Fernando Mota: Abbvie,\u00a0Almirall,\u00a0Amgen,\u00a0Boehringer Ingelheim, Galderma, Johnson & Johnson, LEO Pharma, Lilly, Novartis, Organon, Pfizer, Pierre Fabre, Sanofi Genzyme. These disclosures reflect engagements in roles such as consultancy, advisory, speaker participation, or involvement in clinical research. Diana Louren\u00e7o is an employee of Johnson & Johnson Innovative Medicine, Portugal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board or independent ethics committee at each participating center. The CERES study was a national, prospective, noninterventional, real-world observational study conducted under routine clinical practice in Portugal, with no assignment of treatment, no randomization, and no deviation from standard of care; all treatment decisions were made independently by the treating physicians prior to and irrespective of study participation. In accordance with applicable national and international regulations, non-interventional observational studies of this nature are not required to be registered in public clinical trial registries. The study was conducted in compliance with all ethical and regulatory requirements, and written informed consent was obtained from all patients prior to inclusion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}